Drug Trial Radar · NCT07356466
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
100
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
Apr 30, 2027
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- Fujian Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.
Conditions
- Gastric (Stomach) Cancer
Interventions
Pucotenlimab Combined with LenvatinibDrug
Pucotenlimab Combined with Lenvatinib
Oxaliplatin plus S-1 regimenDrug
Oxaliplatin plus S-1 regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: 30day
- Objective Response RateTime frame: 30day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.